Well, we've got a stable cell line for production:
Patrys Establishes Stable Cell Line for Production of PAT-DX1
https://www.patrys.com/site/market-announcements/2021/663%20Patrys%20Successfully%20Establishes%20PAT-DX1%20Stable%20Cell%20Line_10%20February%202021.pdf
Melbourne, Australia; 10 February 2021: Patrys Limited (ASX: PAB, “Patrys” or the Company), a therapeutic antibody development company, is pleased to announce it has selected an optimised stable cell line for its lead asset PAT-DX1. This important step allows the company to establish largescale production of PAT-DX1 deoxymab for final preclinical studies, first-in-man studies, and partnering activities.
Ann: Response to ASX Query, page-32
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.46M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $1.336K | 167K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 8034700 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1996944 | 7 |
View Market Depth
| Last trade - 10.20am 24/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |